Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge

Rs 2 crore property bought 5 years ago still at Rs 2 crore? Expert explains real challenge in luxury realty

SBI, PNB, BoB drive strongest PSU bank rally in 2 months; what's behind the surge?

Crafting Bharat–Season 3 Episode 5 features Akshay Mehrotra of Fibe 

470% Dividend Declared: This wire maker announces Rs 47 dividend; check record date

The acquisition will include Ivia Beaute's brands namely Astaberry, Ikin and Bhimsaini on a worldwide basis, the company said.

Cipla to acquire Ivia Beaute's cosmetics, personal care distribution and marketing biz for Rs 130 crore

Sanofi India share price,&nbsp;Cipla share price:&nbsp;Shares of pharmaceutical companies Sanofi India and Cipla gained on Wednesday, March 27, after the firms announced an exclusive distribution tie-up for expanding the reach of Sanofi’s Central Nervous System (CNS) portfolio, including its six brands.

Sanofi India, Cipla shares rise on exclusive distribution tie-up

Cipla share price: Cipla's stock was trading up by 2.11 per cent, or Rs 31.30, at Rs 1513.25 at 10:43 am on Monday. The stock that closed at Rs 1481.95 on Friday started its trading session on Monday at Rs 1490.35.

&nbsp;

Pharma giant Cipla hits all-time high, stock surges over 70% in one year

Cipla share price NSE, BSE:&nbsp;Cipla shares looked almost prepared to register a fresh all-time high in a special session on Saturday, March 2, after the US drug regulator completed inspections at a facility of the Mumbai-headquartered pharma company's Chinese subsidiary, Cipla Jiangsu, with zero observations.&nbsp;

Cipla shares trade within inches of record high; check out latest triggers for drug maker

"Product launches through delisting strategy and as well as inorganic partnerships and acquisitions will remain one of our key priorities for the US market," Cipla Global Chief Financial Officer Ashish Adukia said in an analyst call.

Cipla eyes acquisitions, inorganic partnerships in US market

Shares of Cipla dipped 3% as Samina Hamied resigned as executive vice-chair, transitioning to a non-executive director role. The move is part of a broader strategy to professionalize Cipla's management, akin to conglomerates like the Tata Group. Balram Bhargava was appointed as an additional independent director, bringing over 35 years of global public health leadership experience.

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

As of 9:56 a.m., shares of drug major Cipla traded 6.85 per cent or Rs 89.85, higher on the BSE at Rs 1,402.45 apiece. The market capitalisation of the company at around the same time stood at Rs 1,13,227.87 crore.

Cipla posts better-than-estimated Q3 results; stock hits all-time high 

The Mumbai-based company had posted a consolidated net profit of Rs 801 crore in the year-ago period, Cipla Ltd said in a statement. Total revenue from operations in the third quarter of the current fiscal rose to Rs 6,604 crore as compared with Rs 5,810 crore in the year-ago period.

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

With the fresh investment, Cipla's total stake in GoApptiv will increase to 22.99 per cent on a fully diluted basis.

Drug maker Cipla invests Rs 42 crore in digital tech company GoApptiv

An improper seal in the pouch may lead to the leakage of powder blend outside the pouch, resulting in a lower content of medicine inside the pack compared to the label claim and potential underdosing, it added.

Seal integrity issue forces Cipla unit to recall one lot of medication in US

Cipla's clarification on USFDA's action, warning letter was received on 8th November, investigation was conducted on 6-17th February, Cipla's share fell by almost 8% yesterday, know the complete details in this video.

Cipla's Reaction to USFDA's Actions on 8th November, WATCH details here

Cipla USFDA news:&nbsp;Cipla said there was no new development requiring additional disclosure on the matter. The sharp fall in Cipla shares on Thursday was triggered by concerns about whether the warning letter will impact the company’s existing products, according to analysts.&nbsp;&nbsp;

Cipla rebounds after drug maker seeks to allay investors’ concerns on its Pithampur facility

Shares of the OMC comapnies logged gains as high as 7 per cent as oil prices continued their southward trajectory amid heavy US stockpiles.

D-Street Newsmakers: Cipla, Honasa Consumer and OMCs among top stocks that were on investors' radar today

Cipla Pithampur facility Indore news:&nbsp;Cipla shares edged lower&nbsp;after the Mumbai-based drugmaker's facility in Pithampur, Indore, received a warning letter from the United States Food and Drug Administration (USFDA).

Cipla shares trade flat after pharma major's Indore unit gets warning letter from USFDA

Stocks to watch today: Nifty settled lower by 0.17 per cent or 33.4 points, while Sensex gave up 187.75 points to close at 65,795.

Mazagon Dock Shipbuilders, Cipla, Kalyan Jewellers among stocks to watch on Monday

Big news related to Cipla Big changes in promoter shareholding possible, may come in passive role #Cipla's promoter management may get big responsibility, Samina Hameed may come in non-executive role, know complete details in this video

Cipla's Promoter Shareholding Faces Possible Revamp with Key Changes

Mumbai-based drug maker Cipla on Friday reported a&nbsp;43.4 per cent year-on-year increase in consoldiated net profit to Rs&nbsp;1,130.9 crore for the July-September period, beating analysts' estimates by a huge margin.&nbsp;

Cipla Q2 Results | Drug maker beats Street estimates with 43% jump in net profit

Cipla shares remained under pressure on Thursday after the US drug regulator issued five observations about a New York-based facility of the company's wholly-owned subsidiary,&nbsp;InvaGen Pharmaceuticals.&nbsp;

Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Torrent has also been in talks with CVC Capital Partners and Bain Capital who might become equity partners in a consortium and contribute as much as a combined $1.5 billion to the deal, sources have said.

Torrent Pharmaceutical in talks with Apollo to borrow up to $1 billion for Cipla bid: Report

Cipla से जुड़ी Big news related to Cipla: Bids to buy promoters' shares will start soon, bids to buy shares possible by the third week of this month.


Big Update On Cipla Pharma: Bids to buy promoters' shares soon-sources

cipla

Cipla shareholders looking to receive the company's final dividend of Rs 13 per share for FY26 needed to own the stock before the ex-dividend date, with the pharma major maintaining its steady dividend payout track record.
 

650% Dividend Alert: Cipla shares to turn ex-dividend on this date; are you eligible for the Rs 13 payout?

Dalal Street just finished yet another eventful week. Zee Business has brought details of seven stocks on brokerages' watchlists. Here's how analysts are viewing these buzzing scrips.

From Bharti Airtel to Dr Reddy's Labs, Stocks in Focus on D-Street | Stock Market | BSE | NSE

Cipla shares surge up to 8 per cent as management signals strong FY27 outlook despite weak Q4 profit; stock recovers 23 per cent from 52-week low on pipeline optimism and US growth bets.
 

Why Cipla shares are surging despite weak Q4 results; here’s what brokerages expect next

Cipla is scheduled to report its financial results for the quarter and the year ended March 31 on Wednesday, May 13. Analysts expect the largecap pharmaceutical company to stage a weak performance for the final three months of FY26. Read on to learn about key expectations in the pharma company's upcoming earnings report.   

Cipla Q4 FY26 Results Preview: Largecap drug maker's PAT likely to slump 40%, margin set to fall by 8%

We're approaching the end of a holiday-shortened trading week, and Zee Business has brought details of seven stocks on brokerages' watchlists. Here's how analysts are viewing these buzzing scrips.

From Zydus to Zomato, Stocks in Focus on D-Street | Stock Market | BSE | NSE

Zee Business

Home

Personal Finance

India

Economy

Tech

Auto

Markets

Jobs

Indian Railways

World

Videos

Photos

Cipla News- Zee Business provides latest news on Cipla, Cipla news Today, Top News on Cipla, update on Cipla Stay updated with business news, breaking news headlines.

Cipla

Cipla to acquire Ivia Beaute's cosmetics, personal care distribution and marketing biz for Rs 130 crore

Sanofi India, Cipla shares rise on exclusive distribution tie-up

Pharma giant Cipla hits all-time high, stock surges over 70% in one year

Cipla shares trade within inches of record high; check out latest triggers for drug maker

Cipla eyes acquisitions, inorganic partnerships in US market

Cipla Shares Slip as Executive Vice-Chair Steps Down | Stock Market News

RECOMMENDED

Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge

Rs 2 crore property bought 5 years ago still at Rs 2 crore? Expert explains real challenge in luxury realty

SBI, PNB, BoB drive strongest PSU bank rally in 2 months; what's behind the surge?

Crafting Bharat–Season 3 Episode 5 features Akshay Mehrotra of Fibe

470% Dividend Declared: This wire maker announces Rs 47 dividend; check record date

Cipla posts better-than-estimated Q3 results; stock hits all-time high

Cipla Q3 results: 32% rise in net profit to Rs 1,056 crore

Drug maker Cipla invests Rs 42 crore in digital tech company GoApptiv

Seal integrity issue forces Cipla unit to recall one lot of medication in US

Cipla's Reaction to USFDA's Actions on 8th November, WATCH details here

Cipla rebounds after drug maker seeks to allay investors’ concerns on its Pithampur facility

D-Street Newsmakers: Cipla, Honasa Consumer and OMCs among top stocks that were on investors' radar today

Cipla shares trade flat after pharma major's Indore unit gets warning letter from USFDA

Mazagon Dock Shipbuilders, Cipla, Kalyan Jewellers among stocks to watch on Monday

Cipla's Promoter Shareholding Faces Possible Revamp with Key Changes

Cipla Q2 Results | Drug maker beats Street estimates with 43% jump in net profit

Cipla unit's US facility receives 5 observations from American drug regulator; shares fall

Torrent Pharmaceutical in talks with Apollo to borrow up to $1 billion for Cipla bid: Report

Big Update On Cipla Pharma: Bids to buy promoters' shares soon-sources

Top News

Infosys and government join hands to tackle risks from Anthropic’s 'Mythos' AI model: Sources

Centre moves closer to launching coal exchange: Explained in 10 points

ATF prices rise 10% after Price Stabilisation Fund takes effect: What it means for passengers

IDBI Disinvestment Update: Govt confident on stake sale, eyes over Rs 80,000 crore monetisation in FY27

Gold imports fall after import duty increase

Gurmeet Chadha-backed Neervana Netzero wins Rajasthan Green Innovation Challenge